Surgery to remove tumors after fast return of ovarian cancer
Part of Women’s health & pregnancy clinical trials.
This trial looks at whether removing as much tumor as possible with surgery can help people whose ovarian/peritoneal/fallopian tube cancer comes back quickly after platinum chemotherapy. It targets cases where the recurrence is limited and may be safely removed, then compares outcomes to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your ovarian, peritoneal, or fallopian tube cancer has come back within 3 recurrences or less (up to 3 prior treatment lines).
- Your cancer returned within 6 months after platinum chemotherapy (and it is not platinum-refractory/uncontrolled).
- Your first surgery was able to leave no visible cancer (“R0 ideal debulking”).
- Scans (PET-CT) suggest the recurrence is mostly in the abdomen, limited to 5 or fewer spots, and you have less than 500 mL fluid (ascites).
- You are in overall good health (ECOG/WHO performance score 0–1).
- Your blood counts and organ tests are adequate (kidney and liver function are within set limits, and blood counts like white cells, neutrophils, and platelets meet thresholds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This Phase 3 trial tests whether patients with advanced ovarian, fallopian tube, or primary peritoneal cancer do better with surgery first versus chemotherapy first. It also groups people based on how extensive the cancer is to choose the best approach.
This trial tests if a second surgery followed by heated chemotherapy delivered directly into the abdomen can help people with ovarian, fallopian tube, or peritoneal cancer whose disease has returned while on a PARP inhibitor.
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
This study tests whether removing the recurrent ovarian tumor with surgery, after chemo has worked well, can help women whose cancer came back more than 6 months after their last platinum chemo. It's for a first recurrence only, and the tumor must be able to be completely removed by surgery.
Hear when a new Cytoreductive Surgery trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.